Pharmaceutical giant Eli Lilly (NYSE: LLY) is having a great year. Shares are up over 50% through the first half of the year on the heels of emerging blockbusters in the diabetes and obesity-care markets.

While sales of Mounjaro and Zepbound are becoming increasingly scrutinized, I'd encourage investors to get up to speed on what else Lilly is working on. In early June, Lilly received some positive news from an advisory panel working alongside the Food and Drug Administration (FDA).

Let's break down what's going on at the company, and what it could mean for long-term investors.

Continue reading

Source Fool.com